Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 15.0x - 16.6x | 15.8x |
| Selected Fwd P/E Multiple | 9.1x - 10.0x | 9.5x |
| Fair Value | €52.75 - €58.30 | €55.53 |
| Upside | 17.5% - 29.9% | 23.7% |
| Benchmarks | - | Full Ticker |
| Amphastar Pharmaceuticals, Inc. | - | NasdaqGS:AMPH |
| Creative Medical Technology Holdings, Inc. | - | NasdaqCM:CELZ |
| Protagonist Therapeutics, Inc. | - | NasdaqGM:PTGX |
| Sonnet BioTherapeutics Holdings, Inc. | - | NasdaqCM:SONN |
| Cytokinetics, Incorporated | - | NasdaqGS:CYTK |
| Halozyme Therapeutics, Inc. | - | DB:RV7 |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| AMPH | CELZ | PTGX | SONN | CYTK | RV7 | |||
| NasdaqGS:AMPH | NasdaqCM:CELZ | NasdaqGM:PTGX | NasdaqCM:SONN | NasdaqGS:CYTK | DB:RV7 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 26.7% | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | 36.9% | NM- | NM- | NM- | NM- | 3.3% | ||
| Latest Twelve Months | -8.4% | -15.4% | -65.3% | -57.7% | -16.0% | 52.2% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 14.6% | -23305.5% | -1108.4% | -10176.9% | -3981.3% | 44.2% | ||
| Prior Fiscal Year | 21.3% | -58739.7% | -131.6% | -12741.6% | -6988.6% | 34.0% | ||
| Latest Fiscal Year | 21.8% | -49940.7% | 63.3% | -39929.3% | -3191.1% | 43.7% | ||
| Latest Twelve Months | 19.4% | -43500.2% | 27.0% | -1328.6% | -3201.5% | 44.8% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 6.1x | 0.1x | 98.6x | -0.1x | -6.8x | 10.8x | ||
| Price / LTM Sales | 1.5x | 488.5x | 16.6x | 3.5x | 206.1x | 6.0x | ||
| LTM P/E Ratio | 7.7x | -1.1x | 61.4x | -0.3x | -6.4x | 13.4x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -6.4x | -0.3x | 61.4x | |||||
| Historical LTM P/E Ratio | 13.8x | 19.2x | 267.8x | |||||
| Selected P/E Multiple | 15.0x | 15.8x | 16.6x | |||||
| (x) LTM Net Income | 485 | 485 | 485 | |||||
| (=) Equity Value | 7,290 | 7,674 | 8,057 | |||||
| (/) Shares Outstanding | 123.2 | 123.2 | 123.2 | |||||
| Implied Value Range | 59.16 | 62.28 | 65.39 | |||||
| FX Rate: USD/EUR | 1.2 | 1.2 | 1.2 | Market Price | ||||
| Implied Value Range (Trading Cur) | 50.54 | 53.20 | 55.86 | 44.88 | ||||
| Upside / (Downside) | 12.6% | 18.5% | 24.5% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | AMPH | CELZ | PTGX | SONN | CYTK | RV7 | |
| Value of Common Equity | 1,088 | 7 | 3,452 | 4 | 3,960 | 6,473 | |
| (/) Shares Outstanding | 47.1 | 2.6 | 62.0 | 3.2 | 119.4 | 123.2 | |
| Implied Stock Price | 23.08 | 2.65 | 55.69 | 1.12 | 33.16 | 52.53 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.17 | |
| Implied Stock Price (Trading Cur) | 23.08 | 2.65 | 55.69 | 1.12 | 33.16 | 44.88 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.17 | |